{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/320143648"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "d ???50,000 50 <700 or <50,000 Hold In general, for severe (Grade 3 or 4) non???hematological toxicity, except alopecia and nausea/vomiting, therapy with Gemzar should be held or decreased by 50% depending on the judgment of the treating physician." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "nih.gov" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/341924609"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/320143648" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/362726466"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/320143648"] } } }
